Tekmira Pharmaceuticals Corporation's LNP Technology Enables Alnylam Pharmaceuticals (ALNY)'s Positive Phase II ALN-TTR02 Data
7/1/2013 7:33:27 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
VANCOUVER, British Columbia, July 1, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) presented positive results from its Phase II clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology.
Help employers find you! Check out all the jobs and post your resume.